Lataa...
High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy
Nimotuzumab (h-R3) is a humanized monoclonal antibody that is safe to use against epidermal growth factor receptor (EGFR). However, the available information is insufficient about the dose effect of monoclonal antibody against epidermal growth factor receptor for the treatment of esophageal squamous...
Tallennettuna:
| Julkaisussa: | Onco Targets Ther |
|---|---|
| Päätekijät: | , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4699509/ https://ncbi.nlm.nih.gov/pubmed/26766917 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S89592 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|